ES2154712T3 - Metodo para diagnosticar la predisposicion al cancer de mama y de ovarios. - Google Patents

Metodo para diagnosticar la predisposicion al cancer de mama y de ovarios.

Info

Publication number
ES2154712T3
ES2154712T3 ES95305602T ES95305602T ES2154712T3 ES 2154712 T3 ES2154712 T3 ES 2154712T3 ES 95305602 T ES95305602 T ES 95305602T ES 95305602 T ES95305602 T ES 95305602T ES 2154712 T3 ES2154712 T3 ES 2154712T3
Authority
ES
Spain
Prior art keywords
human
cancer
ovaries
chest
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95305602T
Other languages
English (en)
Other versions
ES2154712T5 (es
Inventor
Mark H Skolnick
David E Goldgar
Yoshio Miki
Jeff Swensen
Alexander Kamb
Keith D Harshman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
University of Utah Research Foundation Inc
US Department of Health and Human Services
Original Assignee
Myriad Genetics Inc
University of Utah Research Foundation Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27575337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2154712(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/487,002 external-priority patent/US5710001A/en
Priority claimed from US08/483,554 external-priority patent/US5747282A/en
Application filed by Myriad Genetics Inc, University of Utah Research Foundation Inc, US Department of Health and Human Services filed Critical Myriad Genetics Inc
Publication of ES2154712T3 publication Critical patent/ES2154712T3/es
Application granted granted Critical
Publication of ES2154712T5 publication Critical patent/ES2154712T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION SE REFIERE GENERALMENTE AL CAMPO DE LA GENETICA HUMANA. ESPECIFICAMENTE, LA INVENCION SE REFIERE A METODOS Y A MATERIALES UTILIZAR PARA AISLAR Y DETECTAR UN GEN DE PREDISPOSICION DEL CANCER DE PECHO Y DE OVARIOS HUMANO (BRCA1), ALGUNOS ALELOS MUTANTES DEL MISMO PROVOCAN SUSCEPTIBILIDAD HACIA EL CANCER, EN PARTICULAR EL CANCER DE PECHO Y DE OVARIOS. MAS ESPECIFICAMENTE, LA INVENCION SE REFIERE A MUTACIONES EN LA LINEA DE GERMEN EN EL GEN BRCA1 Y A SU USO EN LA DIAGNOSIS DE LA PREDISPOSICION AL CANCER DE PECHO Y DE OVARIOS. LA INVENCION SE REFIERE ADEMAS A MUTACIONES SOMATICAS EN EL GEN BRCA1 EN EL CANCER DE PECHO Y DE OVARIOS HUMANO Y A SU USO EN LA DIAGNOSIS Y PROGNOSIS DEL CANCER DE PECHO Y DE OVARIOS HUMANO. ADICIONALMENTE, LA INVENCION SE REFIERE A LAS MUTACIONES SOMATICAS EN EL GEN BRCA1 EN OTROS CANCERES HUMANOS Y A SU USO EN LA DIAGNOSIS Y PROGNOSIS DE CANCERES HUMANOS.
ES95305602T 1994-08-12 1995-08-11 Metodo para diagnosticar la predisposicion al cancer de mama y de ovarios. Expired - Lifetime ES2154712T5 (es)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US28922194A 1994-08-12 1994-08-12
US289221 1994-08-12
US30026694A 1994-09-02 1994-09-02
US300266 1994-09-02
US30810494A 1994-09-16 1994-09-16
US308104 1994-09-16
US34882494A 1994-11-29 1994-11-29
US348824 1994-11-29
US40930595A 1995-03-24 1995-03-24
US409305 1995-03-24
US48801195A 1995-06-07 1995-06-07
US08/487,002 US5710001A (en) 1994-08-12 1995-06-07 17q-linked breast and ovarian cancer susceptibility gene
US08/483,554 US5747282A (en) 1994-08-12 1995-06-07 17Q-linked breast and ovarian cancer susceptibility gene
US488011 1995-06-07
US483554 1995-06-07
US487002 1995-06-07

Publications (2)

Publication Number Publication Date
ES2154712T3 true ES2154712T3 (es) 2001-04-16
ES2154712T5 ES2154712T5 (es) 2009-12-14

Family

ID=27575337

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95305602T Expired - Lifetime ES2154712T5 (es) 1994-08-12 1995-08-11 Metodo para diagnosticar la predisposicion al cancer de mama y de ovarios.
ES95305601T Expired - Lifetime ES2164136T5 (es) 1994-08-12 1995-08-11 Sondas de acidos nucleicos que copmrenden un fragmento del gen de susceptibilidad al cancer de mama y ovarios asociado a 17q.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95305601T Expired - Lifetime ES2164136T5 (es) 1994-08-12 1995-08-11 Sondas de acidos nucleicos que copmrenden un fragmento del gen de susceptibilidad al cancer de mama y ovarios asociado a 17q.

Country Status (15)

Country Link
EP (2) EP0699754B2 (es)
JP (1) JP3399539B2 (es)
CN (1) CN1159829A (es)
AT (2) ATE198623T1 (es)
AU (2) AU691958B2 (es)
CA (2) CA2196795C (es)
DE (2) DE69519834T3 (es)
DK (2) DK0705902T3 (es)
ES (2) ES2154712T5 (es)
FI (2) FI970514A7 (es)
GR (1) GR3035631T3 (es)
NO (2) NO970625L (es)
NZ (1) NZ291624A (es)
PT (2) PT699754E (es)
WO (2) WO1996005308A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US6403303B1 (en) * 1996-05-14 2002-06-11 Visible Genetics Inc. Method and reagents for testing for mutations in the BRCA1 gene
US6083698A (en) * 1995-09-25 2000-07-04 Oncormed, Inc. Cancer susceptibility mutations of BRCA1
US6951721B2 (en) 1996-02-12 2005-10-04 Gene Logic Inc. Method for determining the haplotype of a human BRCA1 gene
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US6130322A (en) * 1996-02-12 2000-10-10 Gene Logic, Inc. Coding sequences of the human BRCA1 gene
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
WO1998005968A1 (en) 1996-08-02 1998-02-12 The Wistar Institute Of Anatomy And Biology Brca1 associated protein (bap-1) and uses therefor
WO1998012327A2 (en) * 1996-09-20 1998-03-26 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
WO1998025125A2 (en) * 1996-12-03 1998-06-11 Swift Michael R Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
US5965377A (en) * 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
AU754748B2 (en) * 1997-06-04 2002-11-21 Rijksuniversiteit Te Leiden A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
CA2292843A1 (en) * 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US5994096A (en) * 1997-07-25 1999-11-30 Smithkline Beecham Corporation Regulator
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
FR2826012B1 (fr) * 2001-06-13 2003-09-26 Centre Nat Rech Scient Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
FR2836919B1 (fr) * 2002-03-05 2004-07-09 Centre Nat Rech Scient Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
US20060105403A1 (en) * 2001-06-13 2006-05-18 Venezia Nicole D Braca1/acc alpha molecular complexes, diagnostic and therapeutic applications
US7196085B2 (en) 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101037690B (zh) * 2006-03-16 2011-07-20 国家人口计生委科学技术研究所 具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体
WO2007137187A2 (en) 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US7834015B2 (en) 2006-05-31 2010-11-16 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
AU2008313467B2 (en) 2007-10-17 2013-08-29 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4 -fluoro-benzyl] -2H-phthalazin-1-one
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
US8012976B2 (en) 2008-08-06 2011-09-06 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
DK2324127T3 (en) 2008-08-10 2015-04-27 Kuakini Medical Ct A method of using FOXO3A polymorphisms and haplotypes for predicting and healthy aging and longevity
BR122021018683B1 (pt) 2008-10-07 2022-11-16 Kudos Pharmaceuticals Limited Formulação farmacêutica de 4-[3-(4-ciclopropanocarbonil- piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona, uso de um polímero de matriz, forma de dosagem e método para produzir uma dispersão amorfa sólida
CA2743211A1 (en) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
AU2010221721A1 (en) * 2009-02-06 2011-08-18 Yale University A SNP marker of breast and ovarian cancer risk
TW201114756A (en) 2009-07-15 2011-05-01 Astrazeneca Ab Phthalazinone compound
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
CN105525009B (zh) * 2016-01-26 2018-10-16 绍兴华因生物科技有限公司 检测杂合性brca1/2基因缺失的方法及所用引物
SG11202011135WA (en) 2018-05-14 2020-12-30 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
HUE071067T2 (hu) 2019-07-19 2025-07-28 Astrazeneca Ab PARP1 inhibitorok
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113388680B (zh) * 2020-03-14 2023-07-04 复旦大学附属妇产科医院 上皮性卵巢癌靶点ret及其在诊断和治疗中的作用
KR102262529B1 (ko) * 2020-06-15 2021-06-09 연세대학교 산학협력단 Brca 변이성 난소암에 대한 진단 방법 및 이를 이용한 키트
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
BR112023006337A2 (pt) 2020-10-09 2023-05-09 Astrazeneca Uk Ltd Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
KR20230160299A (ko) 2021-03-23 2023-11-23 누베이션 바이오 인크. 항암 핵 호르몬 수용체 표적화 화합물
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US20240366584A1 (en) 2021-06-21 2024-11-07 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
AU2022392822A1 (en) 2021-11-18 2024-05-02 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
IL313661A (en) 2021-12-21 2024-08-01 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
JP2025503511A (ja) 2021-12-28 2025-02-04 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲート及びｒａｓｇ１２ｃ阻害剤の組み合わせ
CA3240724A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
CA3255700A1 (en) 2022-03-16 2023-09-21 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody‑drug conjugate therapy
CN119212702A (zh) 2022-04-07 2024-12-27 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
AU2023248685A1 (en) 2022-04-07 2024-11-14 Astrazeneca Ab Combination therapy for treating cancer
CN118973555A (zh) 2022-04-07 2024-11-15 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
US20250352539A1 (en) 2022-06-15 2025-11-20 Astrazeneca Ab Combination therapy for treating cancer
CA3262449A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A BISPECIFIC CHECKPOINT INHIBITOR
TW202440169A (zh) 2022-11-30 2024-10-16 日商第一三共股份有限公司 抗體-藥物結合物與dnmt抑制劑之組合
TW202523359A (zh) 2023-10-24 2025-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
TW202535479A (zh) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
WO2025153668A1 (en) 2024-01-19 2025-07-24 Astrazeneca Ab Pharmaceutical compositions comprising azd5305
WO2026052764A1 (en) 2024-09-06 2026-03-12 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody drug conjugate therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
DK0507852T3 (da) * 1990-01-04 1999-01-04 Univ Johns Hopkins Gen deleteret hos mennesker med kolorektal cancer
WO1992000311A1 (en) * 1990-06-27 1992-01-09 Princeton University Probes for detecting mutant p53
JPH06503967A (ja) * 1991-01-04 1994-05-12 ベイラー・カレッジ・オブ・メディシン 腫瘍感受性非ヒト動物
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1994000764A1 (en) * 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES The met proto-oncogene and a method for predicting breast cancer progression
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer

Also Published As

Publication number Publication date
NZ291624A (en) 1998-07-28
AU3321695A (en) 1996-03-07
CA2196795C (en) 2001-04-03
NO970626L (no) 1997-04-14
EP0699754B2 (en) 2009-08-12
ATE198623T1 (de) 2001-01-15
EP0705902A1 (en) 1996-04-10
PT705902E (pt) 2002-05-31
FI970514A0 (fi) 1997-02-07
NO970626D0 (no) 1997-02-11
AU3242895A (en) 1996-03-07
EP0699754B1 (en) 2001-01-10
JP3399539B2 (ja) 2003-04-21
EP0705902B2 (en) 2008-08-06
WO1996005307A2 (en) 1996-02-22
ES2164136T5 (es) 2009-02-16
DK0705902T3 (da) 2002-03-11
NO970625L (no) 1997-04-14
DE69524182T3 (de) 2009-07-09
PT699754E (pt) 2001-04-30
FI970514A7 (fi) 1997-04-07
JP2002502227A (ja) 2002-01-22
WO1996005307A3 (en) 1996-03-14
DE69524182D1 (de) 2002-01-10
CN1159829A (zh) 1997-09-17
WO1996005308A1 (en) 1996-02-22
ES2164136T3 (es) 2002-02-16
NO970625D0 (no) 1997-02-11
FI970515A0 (fi) 1997-02-07
AU691331B2 (en) 1998-05-14
GR3035631T3 (en) 2001-06-29
DK0699754T3 (da) 2001-02-26
EP0699754A1 (en) 1996-03-06
ES2154712T5 (es) 2009-12-14
FI970515A7 (fi) 1997-04-07
CA2196795A1 (en) 1996-02-22
DE69519834T3 (de) 2010-04-01
DE69519834T2 (de) 2001-04-26
AU691958B2 (en) 1998-05-28
EP0705902B1 (en) 2001-11-28
DE69524182T2 (de) 2002-05-29
DE69519834D1 (de) 2001-02-15
ATE209660T1 (de) 2001-12-15
CA2196790A1 (en) 1996-02-22
CA2196790C (en) 2000-10-10

Similar Documents

Publication Publication Date Title
ES2158048T3 (es) Mutaciones del gen ligado al cromosoma 17q, de susceptibilidad al cancer de mama y de ovario.
ES2164136T3 (es) Gen de susceptibilidad al cancer de mama y de ovarios asociado a 17q.
ES2190466T3 (es) Gen brca2 de susceptibilidad al cancer de mama ligado al cromosoma 13.
EP1109937A4 (en) A NEW METHOD FOR DIAGNOSIS, EVALUATION, IMAGE DISPLAY AND TREATMENT OF VARIOUS CANCER DISEASES
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
DE69417140D1 (de) Bilderzeugung für die Computertomographie
DK1356030T3 (da) RUNX3 gen, som udviser anti-tumor aktivitet, og anvendelse deraf
DE69833105D1 (de) Verfahren zur feststellung der anwesenheit mutierten brca proteins
ATE424560T1 (de) Marker für neuromyelitis optica
ATE350662T1 (de) Markerproteine für prostatakrebs
IT1246191B (it) Indicatore dell'intensita' di campo nell'ispezione magnetoscopica.
DE60135918D1 (de) Gerät für prostatekrebsdiagnose
ATE327766T1 (de) Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen
ATA19390A (de) Armaturenfamilie, insbesondere für rohrleitungen der mühlenindustrie
MX9701076A (es) Metodo para diagnosticar una predisposicion para cancer de pecho y ovario.
IT7829094A0 (it) 4-alcossi-3,5-diammino-alfa,alfa,alfa-trifluoro metilbenzene, produzione dello stesso e agente di indurimento per il suo elastomero poliuretanico
ES1041597U (es) Dispositivo de engarce para sortijas.
ES262661U (es) "regla para calculo de la capacidad fisica necesaria de un agente extintor".
IT8248827A0 (it) Macchina per la macinazione di grano e/o altri cereali e simili con organi macinanti multipli operanti intorno ad assi verticali
MX9703974A (es) Uso de complejos de metal como agentes de diagnostico de rayos x para el higado y la vesicula biliar.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 699754

Country of ref document: ES